Traveler's Diarrhea

被引：53

作者：

Giddings, Stanley L. ^{[1
]}

Stevens, A. Michel ^{[1
]}

Leung, Daniel T. ^{[1
,2
]}

机构：

[1] Univ Utah, Sch Med, Dept Med, Div Infect Dis, 30 North 1900 East, Salt Lake City, UT 84132 USA

[2] Univ Utah, Sch Med, Dept Pathol, Div Microbiol & Immunol, 15 North Med Dr East, Salt Lake City, UT 84112 USA

来源：

MEDICAL CLINICS OF NORTH AMERICA | 2016年 / 100卷 / 02期

关键词：

Travel; Diarrhea; Risk factors; Epidemiology; Antibiotic prophylaxis; Probiotics; IRRITABLE-BOWEL-SYNDROME; DOUBLE-BLIND; PROSPECTIVE COHORT; SOUTHEAST-ASIA; EPIDEMIOLOGY; PREVENTION; ETIOLOGY; RIFAXIMIN; FLUOROQUINOLONES; SUBSALICYLATE;

D O I：

10.1016/j.mcna.2015.08.017

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Traveler's diarrhea (TD) is the most common travel-related illness, and it can have a significant impact on the traveler. Pretravel consultation provides an excellent opportunity for the clinician to counsel the traveler and discuss strategies such as food and water hygiene, vaccinations, and medications for prophylaxis or self-treatment that may decrease the incidence and impact of TD. Postinfectious sequelae, such as postinfectious irritable bowel syndrome, reactive arthritis, and Guillain-Barre syndrome, may develop weeks or months after return.

引用

页码：317 / +

页数：16

共 57 条

[1] Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): A systematic review and meta-analysis [J].